So by posting this are you thinking 2-73 could be a treatment for Prion diseases....interesting thought, that's thinking out of the box. Nice. But a difficult disease to study. No one would want to be around any patients with a Prion disease. Even Pathologist don't want to do autopsy's on bodies of suspected "infections".
It's a protein that can cause deadly diseases like Creutzfeldt-Jakob Disease. it is not a living organism, but you can consider it "Viral-like".
I am seriously considering putting you on IGNORE if you put up one more post like this. You are welcome to enjoy your "Freedom of Speech", but remember it's not "Freedom of Speech without Consequences".
Well a lot of swing traders and retail longs, but most mutual funds will not buy any stock less than $10. Still considered speculative.
I can't remember but wasn't this old issue discussed in the last Q and A session of the last Qrpt?
When you see the shorts screaming garbage(Phase 3) ...they are very close to COVERING(Phase 4).
Never waste your time with these humps, just place them on IGNORE and move on.
Now even if there are no studies to back up the use of 2-73 for Mild Traumatic Brain Injuries or Vascular Dementia, 2-73 might get some Off-Label use esp with a clean side effect profile there will be little risk in trying 2-73 for MTBI and Vascular Dementia.
IGNORED- your usefulness over. You lost your bung and now shorted. You just don't get it. Adios.
You have no belief in the company, no insight with you dumb reasoning that members here can't understand how complicated the brain is. Well many scientist don't even understand it just yet either. Maybe that's why all the Alzheimer's studies from the last 10 yrs have failed. There is now light at the end of the tunnel. Get on board or keep holding that short.
There may be some competition from ITCI( $26.96) and ACAD ($38.17) , both companies will be doing AD studies too. But AVXL is way ahead at this point a with 2-73 as a treatment and possible disease modifying. Not to mention the greatest potential for big gains with a ridiculously undervalued sp of $1.34.
Tangui Nicolas Maurice, Ph.D.
A member of the Scientific Advisory Board, Dr. Maurice has spent 15 years in the field of neurosciences, including behavioral and molecular neuropharmacology, sigma receptors, neuropeptides, neurosteroids, neurotrophic factors, normal/pathological aging models for Alzheimer’s and related disorders, and behavioral phenotyping of rodent models. Dr. Maurice is a researcher at the Institut national de la sante et de la recherche medicale (INSERM) U710 at Montpellier. He has also held research positions at the Centre National de la Recherche Scientifique (CNRS), INSERM U336, the department of neuropsychopharmacology and hospital pharmacy at Meijo University (Nagoya, Japan), and Jouveinal Research Institute (Fresnes, France).
I would doubt they can produce the drug and sell it on-line, esp with AVXL holding the patent. Looks a little shady so I am thinking that structure they show may not be correct.